Plasminogen activator inhibitors

Jacob Schneiderman*, David J. Loskutoff

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

68 Scopus citations


Plasminogen activator inhibitors (PAIs) regulate plasminogen activation in normal and pathologic processes. Plasminogen activator inhibitor 1 (PAI-1) is the major physiologic inhibitor of both tissue-type and urokinase-type plasminogen activators. It is a highly regulated single-chain glycoprotein, whose overexpression in vivo impairs the fibrinolytic balance and correlates with thrombotic disorders. Recent clinical observations suggest an association between elevated plasma PAI-1 and symptomatic coronary artery occlusive disease or deep venous thrombosis. Recognition of the clinical relevance of PAIs and timely assessment of the fibrinolytic capacity in patients at risk may have therapeutic implications.

Original languageEnglish
Pages (from-to)99-102
Number of pages4
JournalTrends in Cardiovascular Medicine
Issue number3
StatePublished - Apr 1991
Externally publishedYes


Dive into the research topics of 'Plasminogen activator inhibitors'. Together they form a unique fingerprint.

Cite this